Clinician Management Preferences for <i>Clostridioides difficile</i> Infection in Adults: A 2024 Emerging Infections Network Survey
Significant barriers, including high costs, insurance challenges, and limited availability of CDI therapies, impact clinical decision-making and adherence to guideline recommendations.
Authors
- Susan E. Beekmann (ORCID: https://orcid.org/0000-0003-0278-506X)
- Whitney R. Buckel (ORCID: https://orcid.org/0000-0001-9505-2572)
- Philip M. Polgreen (ORCID: https://orcid.org/0000-0002-0630-5898)
- Matthew Lee (ORCID: https://orcid.org/0000-0002-3186-2020)
- Noah Boton (ORCID: https://orcid.org/0000-0002-2917-5125)
- Monica V. Mahoney (ORCID: https://orcid.org/0000-0002-5071-2159)
- Payal Patel (ORCID: https://orcid.org/0000-0001-8666-7313)
- Preeti Mehrotra (ORCID: https://orcid.org/0000-0002-3192-5466)
Institutions
- Intermountain Healthcare (US)
- University of Iowa (US)
- Beth Israel Deaconess Medical Center (US)
- NYU Langone Health (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1093/ofid/ofaf335
- Citations
- 3
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 4.19